Abstract
Background: Oxaliplatin-based electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC-OX) is an emerging treatment option for patients with unresectable colorectal peritoneal metastases (CPM). CRC-PIPAC was the first trial that prospectively investigated repetitive ePIPAC-OX monotherapy without concomitant systemic therapy for patients with unresectable colorectal peritoneal metastases. The present study assessed the total costs of repetitive ePIPAC-OX monotherapy.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call